CARA insider filings
Cara Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-03-04. Screen CARA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CARA between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — Cara Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-03-04 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Sale (S): 583 @ $4.75 | EDGAR |
| 2025-03-04 | 4 | Terrillion Scott — SEC'Y; CHIEF COMPLIANCE & G.C. | Sale (S): 163 @ $4.76 | EDGAR |
| 2025-02-06 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Sale (S): 372 @ $4.72 | EDGAR |
| 2024-11-06 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Sale (S): 3,668 @ $0.29 | EDGAR |
| 2024-08-02 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Sale (S): 4,149 @ $0.35 | EDGAR |
| 2024-06-06 | 4 | Boudreau Helen M — Director | Grant/award (A): 150,647 @ $0 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | von Moltke Lisa — Director | Grant/award (A): 150,647 @ $0 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Ives Jeffrey L. — Director | Grant/award (A): 150,647 @ $0 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Shiff Susan Ph.D. — Director | Grant/award (A): 150,647 @ $0 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | VOGELBAUM MARTIN — Director | Grant/award (A): 301,295 @ $0 · Grant/award (A): 390,000 (derivative) @ $0 | EDGAR |
| 2024-05-06 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Sale (S): 3,936 @ $0.75 | EDGAR |
| 2024-04-09 | 4 | Goncalves Joana — CHIEF MEDICAL OFFICER | Sale (S): 2,753 @ $0.83 | EDGAR |
| 2024-04-09 | 4 | Terrillion Scott — SEC'Y; CHIEF COMPLIANCE & G.C. | Sale (S): 2,753 @ $0.83 | EDGAR |
| 2024-03-04 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Sale (S): 5,834 @ $0.89 | EDGAR |
| 2024-03-04 | 4 | Terrillion Scott — SEC'Y; CHIEF COMPLIANCE & G.C. | Sale (S): 3,293 @ $0.89 | EDGAR |
| 2024-03-04 | 4 | Goncalves Joana — CHIEF MEDICAL OFFICER | Sale (S): 3,293 @ $0.89 | EDGAR |
| 2024-02-12 | 4 | Terrillion Scott — SEC'Y; CHIEF COMPLIANCE & G.C. | Sale (S): 7,770 @ $0.53 | EDGAR |
| 2024-02-12 | 4 | Maynard Ryan D — CHIEF FINANCIAL OFFICER | Sale (S): 5,488 @ $0.53 | EDGAR |
| 2024-02-12 | 4 | Goncalves Joana — CHIEF MEDICAL OFFICER | Sale (S): 7,770 @ $0.53 | EDGAR |
| 2024-02-12 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Sale (S): 35,575 @ $0.53 | EDGAR |
| 2024-02-05 | 4 | Terrillion Scott — SEC'Y; CHIEF COMPLIANCE & G.C. | Grant/award (A): 13,500 @ $0 | EDGAR |
| 2024-02-05 | 4 | Maynard Ryan D — CHIEF FINANCIAL OFFICER | Grant/award (A): 13,500 @ $0 | EDGAR |
| 2024-02-05 | 4 | Goncalves Joana — CHIEF MEDICAL OFFICER | Grant/award (A): 13,500 @ $0 | EDGAR |
| 2024-02-05 | 4 | Menzaghi Frederique Ph.D. — CHIEF SCIENTIFIC OFF,SVP-R&D | Grant/award (A): 13,500 @ $0 | EDGAR |
| 2024-02-05 | 4 | Posner Christopher — PRESIDENT AND CEO, Director | Grant/award (A): 62,500 @ $0 · Sale (S): 4,981 @ $0.55 | EDGAR |
| 2023-11-03 | 4 | Posner Christopher — President and CEO, Director | Sale (S): 3,796 @ $1.22 | EDGAR |
| 2023-08-04 | 4 | Posner Christopher — President and CEO, Director | Sale (S): 4,307 @ $3.07 | EDGAR |
| 2023-08-04 | 4 | Boudreau Helen M — Director | Grant/award (A): 155,747 (derivative) @ $0 | EDGAR |
| 2023-06-27 | 4 | Terrillion Scott — Sec'y; Chief Compliance & G.C. | Sale (S): 2,483 @ $3.51 | EDGAR |
| 2023-06-27 | 4 | Menzaghi Frederique Ph.D. — Chief Scientific Off,SVP-R&D | Sale (S): 2,993 @ $3.51 | EDGAR |
| 2023-06-27 | 4 | Goncalves Joana — Chief Medical Officer | Sale (S): 2,723 @ $3.51 | EDGAR |
| 2023-06-05 | 4 | von Moltke Lisa — Director | Grant/award (A): 32,362 @ $0 · Grant/award (A): 44,961 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Shiff Susan Ph.D. — Director | Grant/award (A): 32,362 @ $0 · Grant/award (A): 44,961 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Ives Jeffrey L. — Director | Grant/award (A): 32,362 @ $0 · Grant/award (A): 44,961 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | VOGELBAUM MARTIN — Director | Grant/award (A): 64,724 @ $0 · Grant/award (A): 89,923 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | BAINS HARRISON M JR — Director | Grant/award (A): 32,362 @ $0 · Grant/award (A): 44,961 (derivative) @ $0 | EDGAR |
| 2023-05-09 | 4 | Posner Christopher — President and CEO, Director | Sale (S): 3,869 @ $4.40 | EDGAR |
| 2023-04-06 | 4 | Terrillion Scott — Sec'y; Chief Compliance & G.C. | Sale (S): 2,481 @ $4.91 | EDGAR |
| 2023-04-06 | 4 | Goncalves Joana — Chief Medical Officer | Sale (S): 2,481 @ $4.91 | EDGAR |
| 2023-04-06 | 4 | Menzaghi Frederique Ph.D. — Chief Scientific Off,SVP-R&D | Sale (S): 2,733 @ $4.91 | EDGAR |
| 2023-03-07 | 4 | Posner Christopher — President and CEO, Director | Sale (S): 5,987 @ $9.71 | EDGAR |
| 2023-03-07 | 4 | Menzaghi Frederique Ph.D. — Chief Scientific Off,SVP-R&D | Sale (S): 6,802 @ $9.71 | EDGAR |
| 2023-03-07 | 4 | Terrillion Scott — Sec'y; Chief Compliance & G.C. | Sale (S): 6,256 @ $9.71 | EDGAR |
| 2023-03-07 | 4 | Goncalves Joana — Chief Medical Officer | Sale (S): 6,221 @ $9.71 | EDGAR |
| 2023-03-03 | 4 | Terrillion Scott — Sec'y; Chief Compliance & G.C. | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Maynard Ryan D — Chief Financial Officer | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Goncalves Joana — Chief Medical Officer | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Menzaghi Frederique Ph.D. — Chief Scientific Off,SVP-R&D | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Posner Christopher — President and CEO, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2023-02-17 | 4 | Goncalves Joana — Chief Medical Officer | Sale (S): 2,265 @ $10.20 | EDGAR |
Recent 8-K events — Cara Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-01-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CARA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →